Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Number of subsequent treatments and time to recurrence in hepatocellular carcinoma.
Authors
Juan Jose Juarez
Beth Israel Deaconess Medical Center, Boston, MA
Juan Jose Juarez , Vaibhav Birda , Santiago Sucre , Esteban Garita , Kevin Pacheco-Barrios , Rodrigo Paredes , Andrea J. Bullock , Ammar Sarwar , Mary Linton Bounetheau Peters
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 526)
DOI
10.1200/JCO.2024.42.3_suppl.526
Abstract #
526
Poster Bd #
E13
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world clinical characteristics and treatment patterns among people with hepatocellular carcinoma in the United States (US) treated with resection or ablation.
First Author: Neehar Parikh
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Achievement of cancer- and treatment-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: A multicenter cohort study.
First Author: Masatoshi Kudo
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Liver-directed combined radiotherapy for downstaging of over the Milan advanced hepatocellular carcinoma converting to liver transplantation.
First Author: Yong Tae Kim
Poster
2022 ASCO Annual Meeting
IMMUTACE: A biomarker-orientated phase II, single-arm, open-label AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma (HCC; AIO-HEP-0217)—Updated efficacy results.
First Author: Anna Saborowski